June 11, 2020 / 1:23 PM / a month ago

BRIEF-Emergent Biosolutions To Become U.S. Manufacturing Partner For Astrazeneca's Covid-19 Vaccine Candidate

June 11 (Reuters) - Emergent BioSolutions Inc:

* EMERGENT BIOSOLUTIONS SIGNS AGREEMENT TO BE U.S. MANUFACTURING PARTNER FOR ASTRAZENECA’S COVID-19 VACCINE CANDIDATE

* EMERGENT BIOSOLUTIONS - AGREEMENT VALUED AT APPROXIMATELY $87 MILLION

* EMERGENT BIOSOLUTIONS - TO PROVIDE DEVELOPMENT, MANUFACTURING SERVICES & CAPACITY TO INNOVATORS OF LEADING COVID-19 VACCINE CANDIDATES SELECTED BY U.S. GOVERNMENT

* EMERGENT BIOSOLUTIONS INC - UNDER AGREEMENT, CO WILL RESERVE CERTAIN LARGE-SCALE MANUFACTURING CAPACITY THROUGH 2020 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below